[1]杨 洁,廖 萍,黄志平,等.二维超声及弹性成像预测三阴性乳腺癌新辅助化疗效果的价值[J].医学信息,2021,34(13):173-175.[doi:10.3969/j.issn.1006-1959.2021.13.048]
　YANG Jie,LIAO Ping,HUANG Zhi-ping,et al.The Value of Two-dimensional Ultrasound and Elastography in Predicting the Effect of Neoadjuvant Chemotherapy for Triple-negative Breast Cancer[J].Medical Information,2021,34(13):173-175.[doi:10.3969/j.issn.1006-1959.2021.13.048]
点击复制

二维超声及弹性成像预测三阴性乳腺癌新辅助化疗效果的价值()
分享到：

医学信息[ISSN:1006-1959/CN:61-1278/R]

卷:
34卷
期数:
2021年13期
页码:
173-175
栏目:
诊疗技术
出版日期:
2021-07-01

文章信息/Info

Title:
The Value of Two-dimensional Ultrasound and Elastography in Predicting the Effect of Neoadjuvant Chemotherapy for Triple-negative Breast Cancer
文章编号:
1006-1959（2021）13-0173-03
作者:
杨 洁; 廖 萍; 黄志平; 等
（赣州市人民医院超声科1，病理科2，甲状腺乳腺外科3，江西 赣州 341000）
Author(s):
YANG Jie; LIAO Ping; HUANG Zhi-ping; et al.
(Department of Ultrasound1,Department of Pathology2,Department of Thyroid and Breast Surgery3, Ganzhou People’s Hospital,Ganzhou 341000,Jiangxi,China)
关键词:
三阴性乳腺癌; 新辅助化疗; 二维超声; 弹性成像
Keywords:
Triple-negative breast cancer; Neoadjuvant chemotherapy; Two-dimensional ultrasound;  Elastography
分类号:
R445.1
DOI:
10.3969/j.issn.1006-1959.2021.13.048
文献标志码:
A
摘要:
目的 探讨二维超声与弹性成像评估三阴性乳腺癌新辅助化疗的预后价值与意义。方法 选取我院2012年7月~2020年10月收治的Ⅱ~Ⅲ期三阴性乳腺癌患者32例，分别行二维超声（灰阶+彩色多普勒血流）与弹性成像检查，记录化疗前后病灶基线最长径总和、血流信号、弹性评分及弹性应变比，分析其与患者3、5年总生存率、无瘤生存率及复发与转移的相关性。结果 化疗后病灶基线最长径总和评价有效的患者3、5年总生存率、无瘤生存率均高于无效患者（P＜0.05）；弹性应变比值增高的患者3、5年总生存率、无瘤生存率高于降低患者（P＜0.05）；不同血流信号和弹性评分的患者3、5年总生存率、无瘤生存率基本一致（P＞0.05）；不同弹性应变比的患者复发或转移率接近（P＜0.05）；不同病灶基线最长径总和、血流信号及弹性评分的患者复发或转移率差异不大（P＞0.05）。结论 二维超声与弹性成像可有效预测三阴性乳腺癌患者新辅助化疗的效果，可为临床制定患者的治疗方案及预后判断提供参考。
Abstract:
Objective To explore the prognostic value and significance of two-dimensional ultrasound and elastography in evaluating neoadjuvant chemotherapy for triple-negative breast cancer.Methods A total of 32 patients with stage Ⅱ-Ⅲ triple-negative breast cancer who were admitted to our hospital from July 2012 to October 2020 were selected for two-dimensional ultrasound (gray scale + color Doppler blood flow) and elastography.The baseline longest diameter sum, blood flow signal, elasticity score, and elastic strain ratio of the lesion before and after chemotherapy were recorded, and the correlation with the 3, 5-year overall survival rate, tumor-free survival rate, recurrence and metastasis was analyzed.Results After chemotherapy, the 3, 5-year overall survival rate and tumor-free survival rate of patients with effective baseline assessment of the sum of the longest diameter of the lesion were higher than those of ineffective patients(P<0.05);The 3, 5-year overall survival rate and tumor-free survival rate of patients with increased elastic strain ratio were higher than those with decreased patients(P<0.05);There was no statistically significant difference in the 3, 5-year overall survival rate and tumor-free survival rate of patients with different blood flow signals and elasticity scores (P>0.05);The recurrence or metastasis rate of patients with different elastic strain ratios was compared,the difference was statistically significant (P<0.05);There was no statistically significant difference in the recurrence or metastasis rate of patients with different baseline longest diameter sum, blood flow signal and elasticity score (P>0.05).Conclusion Two-dimensional ultrasound and elastography can effectively predict the effect of neoadjuvant chemotherapy in patients with triple-negative breast cancer, and can provide references for clinical treatment plans and prognostic judgments.

参考文献/References:

[1]涂强.lncRNAs 在三阴性乳腺癌发生发展中的作用[J].医学信息,2020,33(10):37-39. [2]中国抗癌协会乳腺癌专业委员会.中国抗癌协会乳腺癌诊治指南与规范（2019年版）[J].中国癌症杂志,2019,29(8):609-608. [3]周立民,王贻东,王长青,等.中晚期乳腺癌患者经新辅助化疗联合保乳手术治疗的临床效果观察[J].泰山医学院学报,2018,39(1):63-64. [4]杨洁,黄志平,廖萍,等.三阴性乳腺癌新辅助化疗 TAC方案效果的超声评价[J].中国超声医学杂志,2016,32(10):953-955. [5]李俊来,李昶田,薛小伟.乳腺弹性成像原理及质量控制[J].中国超声医学杂志,2017,33(7):667-670. [6]李娜,王丹丹,罗娅红,等.动态增强磁共振成像定量参数对乳腺癌新辅助化疗疗效评价及相关性研究[J].肿瘤影像学,2020,29(3):330-335. [7]江姗姗,刘表虎,刘超美,等.超声弹性成像评分法联合面积比法在BI-RADS4 类乳腺肿块诊断中的价值[J].皖南医学院学报,2020,39(5):473-475. [8]郑梅娟,薛恩生,林振湖,等.BI-RADS联合弹性评分及弹性应变率比值对乳腺病灶的诊断价值[J].肿瘤影像学,2020,29(5):436-441. [9]Li JW,Zhang K,Shi ZT,et al.Triple-negative invasive breast carcinoma:the association between the sonographic appearances withclinicopathological feature[J].Sci Rep 2018,8(1):9040. [10]姜山.新辅助化疗后未达pCR的三阴性乳腺癌患者远处转移危险因素研究[D].郑州大学,2020. [11]徐乘骏,张朝蓬,邱恒,等.分子分型对乳腺癌新辅助化疗后肿瘤退缩模式的影响[J].中国肿瘤临床,2018,45(17):894-897.

相似文献/References:

[1]屈欣然.DCE-MRI对局部进展期乳腺癌新辅助化疗的临床指导价值研究[J].医学信息,2018,31(04):34.[doi:10.3969/j.issn.1006-1959.2018.04.012]
　QU Xin-ran.Clinical Value of DCE-MRI in Neoadjuvant Chemotherapy for Locally Advanced Breast Cancer[J].Medical Information,2018,31(13):34.[doi:10.3969/j.issn.1006-1959.2018.04.012]
[2]王文重,伊 扬,董晓昕,等.食管癌患者新辅助化疗前后生理指标变化及意义[J].医学信息,2022,35(09):116.[doi:10.3969/j.issn.1006-1959.2022.09.029]
　WANG Wen-zhong,YI Yang,DONG Xiao-xin,et al.Changes and Significance of Physiological Indexes in Esophageal Cancer Patients Before and After Neoadjuvant Chemotherapy[J].Medical Information,2022,35(13):116.[doi:10.3969/j.issn.1006-1959.2022.09.029]
[3]张 虎,张 涛,徐 芳,等.MRI在乳腺癌诊治中的研究进展[J].医学信息,2022,35(10):62.[doi:10.3969/j.issn.1006-1959.2022.10.015]
　ZHANG Hu,ZHANG Tao,XU Fang,et al.Research Progress of MRI in Diagnosis and Treatment of Breast Cancer[J].Medical Information,2022,35(13):62.[doi:10.3969/j.issn.1006-1959.2022.10.015]
[4]苏 志,吴 蔚,吴智钢,等.含洛铂方案新辅助化疗结合保肢手术治疗骨肉瘤的临床疗效观察[J].医学信息,2018,31(21):83.[doi:10.3969/j.issn.1006-1959.2018.21.022]
　SU Zhi,WU Wei,WU Zhi-gang,et al.Clinical Efficacy of Neoadjuvant Chemotherapy with Lobaplatin Combined with Limb Salvage Surgery for OsteosarcomaC[J].Medical Information,2018,31(13):83.[doi:10.3969/j.issn.1006-1959.2018.21.022]
[5]王绥能,梁贤文,孙 光,等.伊立替康新辅助化疗在进展期胃癌的临床意义[J].医学信息,2018,31(24):164.[doi:10.3969/j.issn.1006-1959.2018.24.050]
　WANG Sui-neng,LIANG Xian-wen,SUN Guang,et al.Clinical Significance of Irinotecan Neoadjuvant Chemotherapy in Advanced Gastric Carcinoma[J].Medical Information,2018,31(13):164.[doi:10.3969/j.issn.1006-1959.2018.24.050]
[6]黄 雨,楼浩男,涂 刚.Luminal B型乳腺癌TEC新辅助化疗疗效及影响因素分析[J].医学信息,2019,32(04):104.[doi:10.3969/j.issn.1006-1959.2019.04.033]
　HUANG Yu,LOU Hao-nan,TU Gang.Analysis of the Efficacy and Influencing Factors of Neoadjuvant Chemotherapy for Luminal B Breast Cancer[J].Medical Information,2019,32(13):104.[doi:10.3969/j.issn.1006-1959.2019.04.033]
[7]李 博,李春晓.新辅助化疗在宫颈癌治疗中的应用[J].医学信息,2019,32(15):106.[doi:10.3969/j.issn.1006-1959.2019.15.034]
　LI Bo,LI Chun-xiao.Application of Neoadjuvant Chemotherapy in the Treatment of Cervical Cancer[J].Medical Information,2019,32(13):106.[doi:10.3969/j.issn.1006-1959.2019.15.034]
[8]徐忆芳,罗秀丽.基于数据挖掘的罗秀丽教授治疗三阴性乳腺癌的临床经验研究[J].医学信息,2019,32(20):159.[doi:10.3969/j.issn.1006-1959.2019.20.050]
　XU Yi-fang,LUO Xiu-li.Professor Luo Xiuli's Clinical Experience in Treating Triple-negative Breast Cancer Based on Data Mining[J].Medical Information,2019,32(13):159.[doi:10.3969/j.issn.1006-1959.2019.20.050]
[9]关利平,李建文.凝血相关指标与乳腺癌新辅助化疗疗效预测的相关性研究[J].医学信息,2022,35(16):159.[doi:10.3969/j.issn.1006-1959.2022.16.041]
　GUAN Li-ping,LI Jian-wen.Study on Correlation Between Coagulation- related Indexes and Efficacy Prediction of Neoadjuvant Chemotherapy for Breast Cancer[J].Medical Information,2022,35(13):159.[doi:10.3969/j.issn.1006-1959.2022.16.041]
[10]贾秀鹏,蒙伶俐,李海莉,等.三阴性乳腺癌与非三阴性乳腺癌组织中PD-1、PD-L1、FOXP3的差异表达及其临床意义[J].医学信息,2021,34(21):7.[doi:10.3969/j.issn.1006-1959.2021.21.002]
　JIA Xiu-peng,MENG Ling-li,LI Hai-li,et al.Differential Expression and Clinical Significance of PD-1, PD-L1 and FOXP3 in Triple-negative Breast Cancer and Non-triple-negative Breast Cancer Tissues[J].Medical Information,2021,34(13):7.[doi:10.3969/j.issn.1006-1959.2021.21.002]
[11]石少庆,宋丽丽.紫杉醇联合卡铂方案在三阴性乳腺癌新辅助化疗中的治疗效果及对患者病理变化的影响[J].医学信息,2023,36(02):145.[doi:10.3969/j.issn.1006-1959.2023.02.031]
　SHI Shao-qing,SONG Li-li.The Therapeutic Effect of Paclitaxel Combined with Carboplatin in Neoadjuvant Chemotherapy for Triple Negative Breast Cancer and its Effect on Pathological Changes[J].Medical Information,2023,36(13):145.[doi:10.3969/j.issn.1006-1959.2023.02.031]

更新日期/Last Update: 1900-01-01